Source: Siyu MedTech; Editor: Liu XinyiReprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
On December 11, 2023, Medtronic (NYSE: MDT) announced an agreement to expand its partnership with Cosmo Intelligent Medical Devices, a wholly-owned subsidiary of Cosmo Pharmaceuticals specializing in medical artificial intelligence technology.
The center of this collaboration is the development by Cosmo Intelligent Medical Devices.GI Genius™ Computer-Aided Polyp Detection System, The focus is onExpand the AI Access™ artificial intelligence platform carried by this system., hoping to involve third-party developers so that the platform can host more third-party AI applications, facilitate faster updates of medical AI applications, and simplify the AI development process.
GI Genius™ Intelligent Endoscopy Module
The agreements reached this time are as follows:- Medtronic pays Cosmo$100 million (approximately RMB 718 million)The advance payment, in addition to which will be paid by the end of 2024$100 million(Approximately 718 million RMB)Potential milestone payments.
- Medtronic, as the global exclusive distributor of the GI Genius™ computer-aided polyp detection system, will pay Cosmo a double-digit percentage royalty on net sales.
# AI Empowered ColonoscopyColorectal cancer is one of the most common malignant tumors, and early diagnosis and screening are crucial. However, the verification process for colorectal cancer is fraught with difficulties. Observing the entire colon accurately with a colonoscope alone is no easy task due to the complex folded structure of the intestines. The bends and folds within the colon can create blind spots in the field of view. Additionally, many colonic lesions closely resemble normal mucosa, which significantly tests the skill of the examining physician.NowWith the support of AI technology, colonoscopy can not only efficiently assist doctors in performing examinations and improve efficiency, but also help reduce the missed detection rate and enhance screening accuracy.。Medtronic's collaboration with Cosmo Intelligent Medical Devices began in 2019. In addition to this partnership, as early as March this year, Medtronic also announced a collaboration withGraphics Card Giant NVIDIA Collaboration, integrating NVIDIA's technology into the GI Genius™ system to accelerate the development of AI in healthcare systems.(Review:Medtronic Partners with Graphics Card Giant to Build AI Endoscopy Platform）# About GI Genius™ Computer-Assisted Polyp Detection SystemGI Genius™ Computer-Aided Polyp Detection System isDeveloped by Cosmo Intelligent Medical Devices, the product wasObtained CE certification in 2019, received approval in Australia, the UAE, and Israel in 2020, and gained FDA approval via a De Novo application in 2021 (the first of its kind).The product isThe first product on the market to use machine learning technology to assist in clinical settingsBedside Doctor: Real-time Detection Device for Colon Lesions of Different Shapes, Sizes, and Forms。The system is highly compatible and can be used by simply connecting to the existing endoscopes, video processors, and monitors of medical institutions. It can also integrate with mainstream brands of endoscope processors available on the market.No need to change the process of colonoscopy.。During system operation, if suspicious lesions are detected, thenWill be marked with a green box on the display., at the same timeAccompanied by brief soundsRemind the doctor to take note.The system's training relies on the colonoscopy video library established by the company, whichContains 13 million polyp images of different shapes and sizes.Compared with standard care (i.e., high-definition white light colonoscopy), the use of the GI Genius™ systemCan improve ADR (adenoma detection rate) and reduce AMR (adenoma miss rate).。According to current research data, the use of this system increases the likelihood of detecting multiple polyps by 50%, the probability of finding distal colon polyps by 53%, and the chance of identifying proximal colon polyps by 28%.# About Cosmo PharmaceuticalsCosmo Pharmaceuticals was founded in 1997, initially as a manufacturing division in Milan purchased by Cosmo S.p.A. from Parke-Davis (now part of the Pfizer Group). The company is currently listed on the Swiss Stock Exchange.The company's total revenue in the first half of the 2023 fiscal year was 43.7 million euros (approximately 335 million RMB).。The company focuses on gastrointestinal diseases and is mainly developing pharmaceutical products based on Multi Matrix MMX® technology, in addition to the GI Genius™ computer-aided polyp detection system.The product features a technology where the surface of the drug tablet is coated with an acid-alkali resistant acrylic copolymer, allowing most of the active pharmaceutical ingredients (API) to successfully reach the intestines, ensuring the drug's efficacy is fully realized.Editor-in-Chief | Zhao Qing Reviewed by | Yi He
